Focus Partners Wealth
ARQT icon

Focus Partners Wealth’s Arcutis Biotherapeutics ARQT Stock Holding History

Focus Partners Wealth’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
62,981
-2,468
-4% -$57.5K ﹤0.01% 1422
2026
Q1 		$1.54M Sell
65,449
-1,124
-2% -$28.7K ﹤0.01% 1428
2025
Q4 		$1.93M Buy
66,573
+1,377
+2% +$35.3K ﹤0.01% 1334
2025
Q3 		$1.24M Buy
65,196
+490
+0.8% +$7.73K ﹤0.01% 1201
2025
Q2 		$907K Buy
64,706
+756
+1% +$10.6K ﹤0.01% 1185
2025
Q1 		$1M Sell
63,950
-233
-0.4% -$3.28K ﹤0.01% 1071
2024
Q4 		$894K Buy
+64,183
New +$703K ﹤0.01% 1090
2024
Q3 		– Sell
-63,100
Closed -$680K – 1578
2024
Q2 		$680K Hold
63,100
– – ﹤0.01% 878
2024
Q1 		$558K Buy
+63,100
New +$471K ﹤0.01% 706

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Focus Partners Wealth's ARQT Position: Q2 2026 in Review

Focus Partners Wealth reduced its Arcutis Biotherapeutics (ARQT) stake by 3.8% in Q2 2026, selling an estimated $57.5K and leaving 62,981 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

Focus Partners Wealth first reported a position in ARQT in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.93M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Focus Partners Wealth held 62,981 shares of Arcutis Biotherapeutics worth $1.65M as of Q2 2026.
  • Focus Partners Wealth sold 2,468 Arcutis Biotherapeutics shares in Q2 2026, an estimated $57.5K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1422 holding.
  • Focus Partners Wealth first reported a position in Arcutis Biotherapeutics in Q1 2024 and has held it in 9 quarters since.
  • Focus Partners Wealth's Arcutis Biotherapeutics position peaked at $1.93M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.